News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kaken Pharmaceuticals To License Its Antifungal Compound KP-103 To Dow Pharmaceutical Sciences


5/11/2006 3:18:58 PM

Tokyo, May 11, 2006 (JCN) - Kaken Pharmaceutical announced on May 10 that it has concluded a licensing agreement with Dow Pharmaceutical Sciences for KP-103, Kaken Pharmaceutical's proprietary antifungal compound.

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES